Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 372

Sort by

Sort Order Select

Journal Articles

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

Andreas Tiede, Ulrich J. Sachs, Andreas Czwalinna, Sonja Werwitzke, Rolf Bikker, Joachim K. Krauss, Frank Donnerstag, Karin Weißenborn, Günter Höglinger, Benjamin Maasoumy, Heiner Wedemeyer, Arnold Ganser

Blood (2021) 138 (4): 350–353.

https://doi.org/10.1182/blood.2021011958

Published: 2021

Includes: Supplemental data

Journal Articles

Redefining outcomes in immune TTP: an international working group consensus report

Adam Cuker, Spero R. Cataland, Paul Coppo, Javier de la Rubia, Kenneth D. Friedman, James N. George, Paul N. Knoebl, Johanna A. Kremer Hovinga, Bernhard Lӓmmle, Masanori Matsumoto, Katerina Pavenski, Flora Peyvandi, Kazuya Sakai, Ravi Sarode, Mari R. Thomas, Yoshiaki Tomiyama, Agnès Veyradier, John-Paul Westwood, Marie Scully

Blood (2021) 137 (14): 1855–1861.

https://doi.org/10.1182/blood.2020009150

Published: 2021

Includes: Supplemental data

Journal Articles

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Blood (2019) 134 (24): 2209–2217.

https://doi.org/10.1182/blood.2019000748

Published: 2019

Includes: Supplemental data

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Katerina Pavenski, MD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Paul Coppo, MD PhD, Flora Peyvandi, MD PhD, Spero Cataland, MD, Ara Metjian, MD, Javier De La Rubia, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2365.

https://doi.org/10.1182/blood-2019-123126

Published: 2019

Journal Articles

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Paul Coppo, MD PhD, Spero Cataland, MD, Flora Peyvandi, MD PhD, Paul Knoebl, MD, Marie Scully, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 2366.

https://doi.org/10.1182/blood-2019-123720

Published: 2019

Journal Articles

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Blood (2019) 134 (Supplement_1): 861.

https://doi.org/10.1182/blood-2019-127992

Published: 2019

Journal Articles

Assessment of the Plasmic Score Utility for Classification of Pediatric Thrombotic Microangiopathies

Grace E Linder, MD, Steven Richard Sloan, MD PhD, Pavan Bendapudi, MD, Robert Makar, MD PhD

Blood (2019) 134 (Supplement_1): 1075.

https://doi.org/10.1182/blood-2019-130608

Published: 2019

Journal Articles

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Isabella McCary, BS, Christine Guelcher, PPCNP-BC, Jan Kuhn, BA, BSN, MSN, Regina Butler, RN-BC, Gita Massey, Michael F. Guerrera, MD, Lance Ballester, MS, Leslie J. Raffini, MD

Blood (2019) 134 (Supplement_1): 1137.

https://doi.org/10.1182/blood-2019-122569

Published: 2019

Journal Articles

Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura

Mouhamed Yazan Abou-Ismail, MD, Yasmin Arafah, MD, Pingfu Fu, PhD, Shufen Cao, Alvin H. Schmaier, MD, Lalitha V. Nayak, MD

Blood (2019) 134 (Supplement_1): 1084.

https://doi.org/10.1182/blood-2019-123537

Published: 2019

Journal Articles

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Javier De La Rubia, Flora Peyvandi, MD PhD, Marie Scully, Spero Cataland, MD, Paul Coppo, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Paul Knoebl, MD, Ara Metjian, MD, Katerina Pavenski, MD, Hilde De Winter, MD, Rui de Passos Sousa, Filip Callewaert

Blood (2019) 134 (Supplement_1): 1093.

https://doi.org/10.1182/blood-2019-124004

Published: 2019

Journal Articles

Severe Bleeding Events in Hemophilia Α Patients Receiving Emicizumab Prophylaxis

Karen L. Zimowski, MD, Glaivy M. Batsuli, MD, Paulette Bryant, MD, Jenny McDaniel, MD, Kelly Tickle, MSN, APN, PPCNP-BC, Shannon L. Meeks, MD, Robert F. Sidonio, Jr., MD MSc

Blood (2019) 134 (Supplement_1): 1126.

https://doi.org/10.1182/blood-2019-126659

Published: 2019

Journal Articles

African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura

Blood (2019) 134 (Supplement_1): 1066.

https://doi.org/10.1182/blood-2019-131064

Published: 2019

Journal Articles

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Spero Cataland, MD, Gema Ariceta, Peter Chen, Bradley Dixon, Katherine Garlo, Laurence Greenbaum, MD PhD, Eric Rondeau, Marie Scully, Stephan Ortiz, RPh, PhD

Blood (2019) 134 (Supplement_1): 1099.

https://doi.org/10.1182/blood-2019-122421

Published: 2019

Journal Articles

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Patrick T. Ebbert, BS, Frederico Xavier, MD MS, Craig D. Seaman, MD MS, Margaret V. Ragni, MD MPH

Blood (2019) 134 (Supplement_1): 2416.

https://doi.org/10.1182/blood-2019-123198

Published: 2019

Journal Articles

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Jerzy Windyga, Pal A Holme, C. Hermans, Ana R Cid, Nirjhar Chatterjee, Hongyu Jiang, Viridiana Cano-Garcia, Carmen Escuriola

Blood (2019) 134 (Supplement_1): 2418.

https://doi.org/10.1182/blood-2019-124324

Published: 2019

Journal Articles

Spectrum of Neurologic Complications after Allogeneic Hematopoietic Cell Transplantation for Hematologic Diseases in Adults: Systematic Review and Meta-Analysis

Maria Gavriilaki, MD, Maria Mainou, MD, Eleni Gavriilaki, MD, Anna-Bettina Haidich, Sotirios Papagiannopoulos, Ioanna Sakellari, Achilles Anagnostopoulos, Vasilis Kimiskidis

Blood (2019) 134 (Supplement_1): 5692.

https://doi.org/10.1182/blood-2019-128641

Published: 2019

Journal Articles

Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant

Sayeef Mirza, MDMPH, Ankita Tandon, DO, Dakota Jenneman, MD, Shu Cao, MD, Ambuj Kumar, MD MPH, Michelle R. Kidd, PharmD, Farhad Khimani, MD, Asmita Mishra, MD, Hien D. Liu, MD, Taiga Nishihori, MD, Lia Perez, MD, Nelli Bejanyan, MD, Joseph Pidala, MD, Michael Nieder, MD, Hany Elmariah, MD MS

Blood (2019) 134 (Supplement_1): 5673.

https://doi.org/10.1182/blood-2019-127370

Published: 2019

Journal Articles

Calcineurin Inhibitors Replacement By Ruxolitinib As Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation

Yanmin Zhao, MD, He Huang, MD PhD

Blood (2019) 134 (Supplement_1): 5674.

https://doi.org/10.1182/blood-2019-125803

Published: 2019

Journal Articles

Veno-Occlusive Disease (VOD) after Hematopoietic Stem Cell Transplant (HSCR): Always a Catastrophic Illness?

Paolo Bernasconi, MD, Anna Amelia Colombo, MD, Daniela Caldera, MD, Oscar Borsani, MD

Blood (2019) 134 (Supplement_1): 5649.

https://doi.org/10.1182/blood-2019-125608

Published: 2019

Journal Articles

Histopathology of Chronic Kidney Disease after Allogeneic Hematopoietic Cell Transplantation: A Multi-Center Observational Study of Kidney Biopsies

Feng Chen, MD PhD, Depei Wu, MD PhD, Ran Wang, MD, Xianghua Huang, MD PhD, Xiaozhong Li, MD PhD, Chaoxing Huang, MD PhD

Blood (2019) 134 (Supplement_1): 5696.

https://doi.org/10.1182/blood-2019-128121

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

Redefining outcomes in immune TTP: an international working group consensus report

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Assessment of the Plasmic Score Utility for Classification of Pediatric Thrombotic Microangiopathies

Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors

Outcomes after Treatment with Upfront Cyclophosphamide or Rituximab for Initial Acquired Thrombotic Thrombocytopenic Purpura

Safety of Caplacizumab in Patients Without Documented Severe ADAMTS13 Deficiency During the HERCULES Study

Severe Bleeding Events in Hemophilia Α Patients Receiving Emicizumab Prophylaxis

African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura

Discordance between Free C5 and CH50 Complement Assays in Measuring Complement C5 Inhibition in Patients with aHUS Treated with Ravulizumab

Emicizumab Prophylaxis in Patients with Hemophilia Α with and without Inhibitors

Real-World Clinical Management of Patients with Hemophilia and Inhibitors: Effectiveness and Safety of aPCC in Patients with >18 Months' Follow-up in the FEIBA Global Outcome Study (FEIBA GO)

Spectrum of Neurologic Complications after Allogeneic Hematopoietic Cell Transplantation for Hematologic Diseases in Adults: Systematic Review and Meta-Analysis

Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant

Calcineurin Inhibitors Replacement By Ruxolitinib As Graft Versus Host Disease Prophylaxis for Patients after Allogeneic Stem Cell Transplantation

Veno-Occlusive Disease (VOD) after Hematopoietic Stem Cell Transplant (HSCR): Always a Catastrophic Illness?

Histopathology of Chronic Kidney Disease after Allogeneic Hematopoietic Cell Transplantation: A Multi-Center Observational Study of Kidney Biopsies

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only